Genzyme Corp. made its case for why it is worth more than Sanofi-Aventis’s $18.5 billion offer, forecasting 2011 profit above Wall Street estimates and sales of $3 billion for its experimental multiple sclerosis drug. Get the full story »
Inside these posts: Multiple sclerosis
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Citizens Bank & Trust execs sued over non-payment
The brothers who helped run failed Citizens Bank & Trust Co. of Chicago are being sued in Cook County Circuit Court over an alleged non-payment of almost $1.6 million.
Delta Trading Co. of Chicago is suing Robert and George Michael for breach of contract.
It said that in January 2007, the brothers borrowed nearly $1.6 million from Marshall & Ilsley Bank. In June 2010, M&I assigned its rights under the note to Delta. Get the full story »
Abbott MS treatment in final clinical trial stage
Abbott Laboratories and its Massachusetts biotech partner have launched a final-stage clinical trial of their experimental treatment for multiple sclerosis.
The first patient — out of 1,500 needed worldwide — was enrolled last month in the U.S. The drug, daclizumab, is being developed for monthly injection under the patient’s skin by North Chicago-based Abbott and Cambridge-based Biogen Idec. Get the full story »
